Coordinatore | CORIS BIOCONCEPT SPRL
Organization address
address: RUE JEAN SONET 4A PARC SCIENTIFIQUE CREALYS LES ISNES contact info |
Nazionalità Coordinatore | Belgium [BE] |
Totale costo | 4˙023˙201 € |
EC contributo | 2˙876˙300 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2011-two-stage |
Funding Scheme | CP-FP |
Anno di inizio | 2012 |
Periodo (anno-mese-giorno) | 2012-01-01 - 2015-06-30 |
# | ||||
---|---|---|---|---|
1 |
CORIS BIOCONCEPT SPRL
Organization address
address: RUE JEAN SONET 4A PARC SCIENTIFIQUE CREALYS LES ISNES contact info |
BE (Gembloux) | coordinator | 552˙100.00 |
2 |
MICROFLUIDIC CHIPSHOP GMBH
Organization address
address: STOCKHOLMER STRASSE 20 contact info |
DE (JENA) | participant | 594˙000.00 |
3 |
PATHOFINDER HOLDING BV
Organization address
address: RANDWYCKSINGEL 45 contact info |
NL (MAASTRICHT) | participant | 499˙000.00 |
4 |
IBM RESEARCH GMBH
Organization address
address: SAEUMERSTRASSE 4 contact info |
CH (RUESCHLIKON) | participant | 482˙200.00 |
5 |
CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE
Organization address
address: Sart Tilman B35 contact info |
BE (LIEGE) | participant | 393˙800.00 |
6 |
INSERM - TRANSFERT SA
Organization address
address: Rue Watt 7 contact info |
FR (PARIS) | participant | 270˙000.00 |
7 |
UNIVERSITEIT ANTWERPEN
Organization address
address: PRINSSTRAAT 13 contact info |
BE (ANTWERPEN) | participant | 85˙200.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Respiratory tract infections (RTIs) are a huge burden in terms of mortality and morbidity worldwide. To improve the management of the bacterial infections of the respiratory tract, the institution of an appropriate antimicrobial therapy as soon as possible has also been shown to be a key element for reducing morbidity and mortality. The aim of our project is to develop a panel of dedicated rapid diagnostic tests to allow the medical staff to link antibiotic prescription on evidence-based diagnosis. In our 3 year project, combining the Multiplex Ligation-dependent Probe Amplification (MLPA) and microfluidic technologies will allow to address the question of viral or bacterial origin. In the case of a bacteria, a second step will allow to identify which bacteria is of interest with its virulence factors and resistance mechanisms. This new tool will be developed for efficient use in clinical settings in order to allow for a better antibiotic resistance management. Several direct impacts will be observed either on public health (decrease of antibiotic pressure), efficiency of treatment for patients (decrease of infectivity and speed in accurate treatments), for diagnostic laboratories (improve in turn around time), for SMEs (better competitiveness) and more generaly on technological innovations.'
Bringing Regenerative Medicine into the market: Allogeneic eASCs Phase IB/IIA clinical trial for treating Rheumatoid Arthritis
Read More